摘要
钠-葡萄糖共转运蛋白2(SGLT2)主要分布在肾近曲小管S1部位,负责肾脏中约90%葡萄糖的重吸收,抑制SGLT2可以促进糖尿病患者尿糖的排出,因此SGLT2抑制剂是一种新型的具有独特作用机制的抗糖尿病药物。本文主要介绍了SGLT2的作用机制以及相比于其他降糖药物的优势,并对已经上市的SGLT2抑制剂进行详细综述,同时对在研阶段的SGLT2抑制剂进行分类总结,为新型选择性SGLT2抑制剂的研发提供参考。
Sodium-glucose co-transporter 2(SGLT2)is distributed in the proximal convoluted tubule S1 of the kidney and is responsible for the reabsorption of about 90%of the glucose in the kidney.Inhibition of SGLT2 can promote the excretion of urine sugar in diabetic patients,so SGLT2 inhibitors are considered to be a new type of anti-diabetic drug with a unique mechanism of action.This article mainly introduces the mechanism of action of SGLT2 and its advantages as compared with other hypoglycemic drugs,and gives an overview of the marketed SGLT2 inhibitors.This article may provide reference for the development and research of new selective SGLT2 inhibitors.
作者
郭家钰
巫振坤
贺岩
吴成军
孙铁民
GUO Jia-yu;WU Zhen-kun;HE Yan;WU Cheng-jun;SUN Tie-min(Innovation Laboratory of Drug Research and Design,Shenyang Pharmaceutical University,Ministry of Education,Shenyang 110016;Department of Pharmacy,General Hospital of Northern Theater Command,Shenyang 110840)
出处
《中南药学》
CAS
2021年第9期1766-1776,共11页
Central South Pharmacy
基金
辽宁省自然科学基金(No.2020LJC06)。
